Agarwood Extract Mitigates Intestinal Injury in Fluorouracil-Induced Mice.
Agarwood Extract Mitigates Intestinal Injury in Fluorouracil-Induced Mice.
复制标题
DOI：
10.1248/bpb.b18-00805
复制
发表时间：
2019-07
影响因子：
2
通讯作者：
Canhong Wang;Shuai Wang;Deqian Peng;Zhangxin Yu;Peng Guo;Jianhe Wei
中科院分区：
文献类型：
--
作者：
Canhong Wang;Shuai Wang;Deqian Peng;Zhangxin Yu;Peng Guo;Jianhe Wei
沉香木被用来治疗胃肠道疾病。虽然我们以前的研究表明，全树沉香诱导技术生产的沉香乙醇提取物(WTAAE)可以改善肠蠕动，但WTAAE的肠道保护作用尚不清楚。本研究旨在评价WTAAE对氟尿嘧啶(5-FU)所致肠损伤的保护作用，并探讨其可能的作用机制。给癌症研究所(ICR)小鼠灌胃沉香木乙醇提取物(AAEs)(详见材料部分)，包括WTAAE(0.71、1.42和2.84g/kg)、野生沉香木乙醇提取物(WAAE)和烧凿沉香木乙醇提取物(FBAAE)(2.84g/kg)。用5-氟尿嘧啶复制大鼠结肠损伤模型。治疗14d后，进行组织病理学、生化及分子指标检测。结果表明，WTAAE可提高肠道推进率，减轻结肠损伤程度，与WAAE相似，但优于FBAAE。同时，还能降低一氧化氮(NO)浓度，升高谷胱甘肽(GSH)和超氧化物歧化酶(SOD)水平。还可降低IL-17、IL-33水平，升高IL-10水平。此外，WTAAE还上调了核因子-E2相关因子2-抗氧化反应元件(NRF2-ARE)途径的基因表达，下调了核因子-kappaB(NF-κB)途径的基因水平。WTAAE具有减轻肠损伤的作用，提示其可作为化学药物所致肠损伤的肠保护和辅助治疗药物。
Agarwood is used to treat gastrointestinal diseases. Although our previous studies demonstrated that agarwood ethanol extract produced by the whole-tree agarwood-inducing technique (WTAAE) improves intestinal peristalsis, the intestinal protective effect of WTAAE remains unclear. This study aimed to evaluate the protective effect of WTAAE on the intestinal injury induced by fluorouracil (5-FU) and explore its potential mechanism. Institute of Cancer Research (ICR) mice were given agarwood ethanol extracts (AAEs) (details in materials part), including WTAAE (0.71, 1.42 and 2.84 g/kg), wild agarwood ethanol extract (WAAE) and burning-chisel-drilling agarwood ethanol extract (FBAAE) (2.84 g/kg). A colon injury model was induced by 5-FU. After 14 d of treatment, the histopathology and biochemical and molecular parameters were measured. Our results indicated that WTAAE enhanced the intestinal advancing rate and alleviated the severity of colon injury similar the WAAE and better than FBAAE. Simultaneously, WTAAE reduced the nitric oxide (NO) concentration and increased the glutathione (GSH) and superoxide dismutase (SOD) levels. WTAAE also reduced the levels of interleukin-17 (IL-17) and IL-33 and elevated the level of IL-10. Furthermore, WTAAE upregulated the mRNA expression of the nuclear factor-E2-related factor 2-antioxidant response element (Nrf2-ARE) pathway and downregulated the mRNA levels of the nuclear factor-kappaB (NF-κB) pathway. WTAAE had a mitigating effect on intestinal damage, suggesting that it could be used as an intestinal protective and adjuvant therapy drug for intestinal injury induced by chemical drugs.